01—Abstract
Summary
Summary of the 8-K filed February 3, 2026. Cited figures are marked; the original filing is the authoritative source.
Amgen reported fourth quarter and full year 2025 results that showed strong top-line momentum but a mixed quality-of-earnings picture.
Full-year total revenues rose 10% to $36.8 billiona, product sales grew 10% to $35.1 billion driven by 13% volume growth, and 14 products exceeded $1 billion in annual sales. GAAP EPS rose 88% to $14.23, though this was flattered by $2.0 billion of net gains on the BeOne equity investment and was partially offset by a $1.2 billion Otezla intangible asset impairment tied to IRA Medicare price setting. Non-GAAP EPS rose 10% to $21.84, and non-GAAP operating margin remained high at 46.1%, though it declined 0.8 points.
Fourth-quarter results were weaker on cash and pricing. Q4 revenue grew 9% to $9.9 billionb, but net selling price fell 4% and non-GAAP EPS was essentially flat at $5.29 as operating expenses rose 16%, driven by R&D up 26% on MariTide and business development. Free cash flow was $1.0 billion in Q4 versus $4.4 billion a year earlier, and $8.1 billion for the full year versus $10.4 billion, largely due to working capital timing.
Debt fell to $54.6 billionc, a 3.2x leverage ratio, and no shares were repurchased during 2025. The outlook is mixed. 2026 guidance calls for revenue of $37.0 to $38.4 billion, non-GAAP EPS of $21.60 to $23.00, and capex of about $2.6 billion.
Management flagged accelerated erosion for Prolia and XGEVA from biosimilars, continued Enbrel and RAVICTI erosion, and a Q1 seasonal pattern. A significant new risk emerged after the period: on January 16, 2026, the FDA asked ChemoCentryx to withdraw TAVNEOS from the U.S. market, which Amgen declined to do on January 28, 2026, and the matter remains under review. Investors should weigh the strong growth in newer products such as Repatha, Tezspire, and Uplizna against pricing pressure, biosimilar competition, rising R&D spend, and the TAVNEOS regulatory overhang.
02—Key points
Key Highlights
- FY2025 total revenues rose 10% to $36.8B, with product sales up 10% on 13% volume growth partially offset by 3% lower net selling price.
- GAAP diluted EPS rose 88% to $14.23, but was boosted by $2.0B of net equity gains (BeOne) and reduced by a $1.2B Otezla impairment tied to IRA Medicare price setting.
- Non-GAAP diluted EPS rose 10% to $21.84 for FY2025, while Q4 non-GAAP EPS was flat at $5.29 as operating expenses rose 16%.
- Free cash flow fell to $8.1B in FY2025 from $10.4B, and Q4 FCF was only $1.0B versus $4.4B a year earlier, mainly due to working capital timing and higher capex.
- Debt was reduced to $54.6B (from $60.1B), with $6.0B retired in 2025, leverage of about 3.2x EBITDA, and no share repurchases in 2025.
- 2026 guidance: revenue of $37.0–38.4B, non-GAAP EPS of $21.60–23.00, GAAP EPS of $15.45–16.94, capex of about $2.6B, and buybacks capped at $3B.
- Key risks: accelerated Prolia/XGEVA erosion from biosimilars, Enbrel and RAVICTI erosion, and FDA's January 2026 request to withdraw TAVNEOS, which Amgen declined on January 28, 2026.
03—Questions
Frequently Asked Questions
How did Amgen's full-year 2025 earnings compare with 2024 on both GAAP and non-GAAP bases?
GAAP diluted EPS rose 88% to $14.23 from $7.56, helped by $2.0B of net gains on the BeOne equity stake and offset by a $1.2B Otezla impairment. Non-GAAP diluted EPS rose 10% to $21.84 from $19.84, driven by revenue growth partially offset by higher operating expenses. Non-GAAP operating income rose to $16.2B from $15.0B.
Why did free cash flow decline so sharply, and is it a concern?
Full-year FCF fell to $8.1B from $10.4B, and Q4 FCF dropped to $1.0B from $4.4B. Management attributed the decline mainly to working capital timing, especially collections, and higher capital expenditures, partly offset by business performance and lower interest payments. Trade receivables rose to $9.6B from $6.8B, so investors should watch whether collections normalize in 2026.
What is the outlook for Amgen's key products in 2026?
Prolia and XGEVA face accelerated erosion as multiple biosimilars have launched globally. Enbrel and Otezla are expected to show a seasonal Q1 dip, and RAVICTI faces continued generic erosion. Repatha is expected to see mid-single-digit net price declines in 2026, though it grew 36% in 2025 on volume. Growth drivers include Tezspire, Uplizna, Imdelltra, and Pavblu.
What is the TAVNEOS situation and how material could it be?
On January 16, 2026, the FDA asked ChemoCentryx to voluntarily withdraw TAVNEOS from the U.S. market, citing concerns about re-adjudicated primary endpoint results for 9 of 331 trial patients and hepatotoxicity risk. Amgen declined to withdraw on January 28, 2026, and is working with the FDA on next steps. TAVNEOS generated $459M in 2025 sales, up 62%, so the outcome is a meaningful revenue risk for 2026 and beyond, though the filing does not quantify a potential impact on guidance.
Why did R&D and operating expenses increase, and what does it mean for margins?
Non-GAAP R&D rose 22% for the full year and 26% in Q4, driven by late-stage programs such as MariTide, early pipeline work, and business development deals. Non-GAAP operating margin fell to 46.1% from 46.9% for the year and to 42.8% in Q4. Management's 2026 guidance implies continued investment, so margins may stay under pressure unless revenue growth from newer products offsets the higher spending.
04—Continue